Cargando…

Development of a novel humanized mouse model for improved evaluation of in vivo anti-cancer effects of anti-PD-1 antibody

Immune checkpoint inhibitors (ICIs) have revolutionized the treatment of cancer in the clinic. Further discovery of novel drugs or therapeutic protocols that enhance efficacy requires reliable animal models that recapitulate human immune responses to ICI treatment in vivo. In this study, we utilized...

Descripción completa

Detalles Bibliográficos
Autores principales:	Katano, Ikumi, Hanazawa, Asami, Otsuka, Iyo, Yamaguchi, Takuya, Mochizuki, Misa, Kawai, Kenji, Ito, Ryoji, Goto, Motohito, Kagawa, Takahiro, Takahashi, Takeshi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8548333/ https://www.ncbi.nlm.nih.gov/pubmed/34702924 http://dx.doi.org/10.1038/s41598-021-00641-8

Ejemplares similares

Generation of Novel Human Red Blood Cell-Bearing Humanized Mouse Models Based on C3-Deficient NOG Mice
por: Yamaguchi, Takuya, et al.
Publicado: (2021)

Generation of Human Immunosuppressive Myeloid Cell Populations in Human Interleukin-6 Transgenic NOG Mice
por: Hanazawa, Asami, et al.
Publicado: (2018)

Enhanced Antibody Responses in a Novel NOG Transgenic Mouse with Restored Lymph Node Organogenesis
por: Takahashi, Takeshi, et al.
Publicado: (2018)

Improved Detection of in vivo Human NK Cell-Mediated Antibody-Dependent Cellular Cytotoxicity Using a Novel NOG-FcγR-Deficient Human IL-15 Transgenic Mouse
por: Katano, Ikumi, et al.
Publicado: (2020)

NOD-Rag2(null) IL-2Rγ(null) Mice: An Alternative to NOG Mice for Generation of Humanized Mice
por: Katano, Ikumi, et al.
Publicado: (2014)

Recent Advances in Allergy Research Using Humanized Mice
por: Ito, Ryoji, et al.
Publicado: (2019)

Development of blastocyst complementation technology without contributions to gametes and the brain
por: Hashimoto, Haruo, et al.
Publicado: (2019)

Anti-PD-1 and Anti-CTLA-4 Therapies in Cancer: Mechanisms of Action, Efficacy, and Limitations
por: Seidel, Judith A., et al.
Publicado: (2018)

Long-term maintenance of peripheral blood derived human NK cells in a novel human IL-15- transgenic NOG mouse
por: Katano, Ikumi, et al.
Publicado: (2017)

Establishment of an integrated automated embryonic manipulation system for producing genetically modified mice
por: Eto, Tomoo, et al.
Publicado: (2021)

Adiponectin deficiency-induced diabetes increases TNFα and FFA via downregulation of PPARα
por: HASHIMOTO, Haruo, et al.
Publicado: (2018)

Cross-reactivity of anti-human programmed cell death ligand 1 (PD-L1) monoclonal antibody, clone 28-8 against feline PD-L1
por: NISHIBORI, Shoma, et al.
Publicado: (2023)

Human PBMC-transferred murine MHC class I/II-deficient NOG mice enable long-term evaluation of human immune responses
por: Yaguchi, Tomonori, et al.
Publicado: (2017)

Prospects of the potential strategies to improve the efficacy of anti‐PD‐1/PD‐L1 therapy
por: Yamaguchi, Hirohito, et al.
Publicado: (2022)

A Novel Enhanced Green FluorescentProtein-Expressing NOG Mouse for Analyzingthe Microenvironment of Xenograft Tissues
por: Higuchi, Yuichiro, et al.
Publicado: (2014)

Anti-PD-1 antibody monotherapy versus anti-PD-1 plus anti-CTLA-4 combination therapy as first-line immunotherapy in unresectable or metastatic mucosal melanoma: a retrospective, multicenter study of 329 Japanese cases (JMAC study)
por: Nakamura, Y., et al.
Publicado: (2021)

Prominent PD-L1-positive M2 macrophage infiltration in gastric cancer with hyper-progression after anti-PD-1 therapy: A case report
por: Yamaguchi, Kyoko, et al.
Publicado: (2021)

The Evolving Landscape of Biomarkers for Anti-PD-1 or Anti-PD-L1 Therapy
por: Tunger, Antje, et al.
Publicado: (2019)

In vitro and in vivo antivirus activity of an anti-programmed death-ligand 1 (PD-L1) rat-bovine chimeric antibody against bovine leukemia virus infection
por: Nishimori, Asami, et al.
Publicado: (2017)

NOG-hIL-4-Tg, a new humanized mouse model for producing tumor antigen-specific IgG antibody by peptide vaccination
por: Kametani, Yoshie, et al.
Publicado: (2017)

Humanized liver TK-NOG mice with functional deletion of hepatic murine cytochrome P450s as a model for studying human drug metabolism
por: Uehara, Shotaro, et al.
Publicado: (2022)

Next generation of anti-PD-L1 Atezolizumab with enhanced anti-tumor efficacy in vivo
por: Li, Maohua, et al.
Publicado: (2021)

Overcoming resistance to anti-PD1 and anti-PD-L1 treatment in gastrointestinal malignancies
por: Puccini, Alberto, et al.
Publicado: (2020)

Anti–PD-1 Monotherapy for Advanced NSCLC Patients with Older Age or Those with Poor Performance Status
por: Matsubara, Taichi, et al.
Publicado: (2021)

Construction of the systemic anticancer immune environment in tumour-bearing humanized mouse by using liposome-encapsulated anti-programmed death ligand 1 antibody-conjugated progesterone
por: Kametani, Yoshie, et al.
Publicado: (2023)

Characteristics and Prognostic Impact of Pneumonitis during Systemic Anti-Cancer Therapy in Patients with Advanced Non-Small-Cell Lung Cancer
por: Fujimoto, Daichi, et al.
Publicado: (2016)

PD-L1 immunohistochemistry for canine cancers and clinical benefit of anti-PD-L1 antibody in dogs with pulmonary metastatic oral malignant melanoma
por: Maekawa, Naoya, et al.
Publicado: (2021)

Hypothalamic–Pituitary Autoimmunity in Patients Treated with Anti-PD-1 and Anti-PD-L1 Antibodies
por: Bellastella, Giuseppe, et al.
Publicado: (2021)

Anti-PD-1/Anti-PD-L1 Drugs and Radiation Therapy: Combinations and Optimization Strategies
por: Boustani, Jihane, et al.
Publicado: (2021)

Development of anti-feline PD-1 antibody and its functional analysis
por: Nishibori, Shoma, et al.
Publicado: (2023)

In vitro and in vivo characterization of anti-malarial acylphenoxazine derivatives prepared from basic blue 3
por: Tougan, Takahiro, et al.
Publicado: (2019)

Efficacy of anti-PD-1 antibodies in NSCLC patients with an EGFR mutation and high PD-L1 expression
por: Masuda, Ken, et al.
Publicado: (2020)

Killer immunoglobulin-like receptor genotype did not correlate with response to anti-PD-1 antibody treatment in a Japanese cohort
por: Ishida, Yoshihiro, et al.
Publicado: (2018)

Are anti-PD1 and anti-PD-L1 alike? The non-small-cell lung cancer paradigm
por: Banna, Giuseppe Luigi, et al.
Publicado: (2020)

Anti–PD-1 and Anti–PD-L1 in Head and Neck Cancer: A Network Meta-Analysis
por: Botticelli, Andrea, et al.
Publicado: (2021)

Author Correction: Next generation of anti-PD-L1 Atezolizumab with enhanced anti-tumor efficacy in vivo
por: Li, Maohua, et al.
Publicado: (2022)

Serum alanine aminotransferase as an early marker of outcomes in patients receiving anti-PD-1 or anti-CTLA-4 antibody
por: Azuma, Takeshi, et al.
Publicado: (2021)

Fulminant Type 1 Diabetes Mellitus Accompanied by Positive Conversion of Anti-insulin Antibody after the Administration of Anti-CTLA-4 Antibody Following the Discontinuation of Anti-PD-1 Antibody
por: Shiba, Michiru, et al.
Publicado: (2018)

The anticancer immune response of anti-PD-1/PD-L1 and the genetic determinants of response to anti-PD-1/PD-L1 antibodies in cancer patients
por: Sui, Xinbing, et al.
Publicado: (2015)

The in vivo Anti‐tumor Effect of Human Recombinant Interleukin‐6
por: Kitahara, Misa, et al.
Publicado: (1990)

Cannot write session to /tmp/vufind_sessions/sess_f99be77dg3ug71vrsn4et8bfv7